Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HTX-034

Small molecule · developed by Heron Therapeutics

Phase 1/2 Most advanced trial (none active)
HRTX Developer
1 Registered trials

What is HTX-034?

HTX-034 is a fixed-dose and individualized-dose combination of bupivacaine, aprepitant and meloxicam. It is studied in patients with bunions and postoperative pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Heron Therapeutics (HRTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04398329 Phase 1/2 Bunions Completed HRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

BunionsPostoperative Pain

More from Heron Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HRTX page.

Follow HRTX, the company behind HTX-034

See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HRTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.